|
Tocris
bepridil hydrochloride ![]() Bepridil Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bepridil+hydrochloride/pmc10651213-70-19-21?v=Tocris Average 90 stars, based on 1 article reviews
bepridil hydrochloride - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
vgcc inhibitor bepridil ![]() Vgcc Inhibitor Bepridil, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bepridil+hydrochloride/pmc06191460-241-1-8?v=Santa+Cruz+Biotechnology Average 88 stars, based on 1 article reviews
vgcc inhibitor bepridil - by Bioz Stars,
2026-07
88/100 stars
|
Buy from Supplier |
|
Sankyo Co
bepridil hydrochloride ![]() Bepridil Hydrochloride, supplied by Sankyo Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/bepridil+hydrochloride/pm16493192-40-54-62?v=Sankyo+Co Average 90 stars, based on 1 article reviews
bepridil hydrochloride - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Bepridil is an amine Calcium channel antagonist that used to treat angina. But it is no longer sold in the United States. It may be a possible option in the treatment of atrial fibrillation.
|
Buy from Supplier |
|
Bepridil hydrochloride is a calcium channel protein inhibitor and antagonist that increases the surface area of red blood cells. Bepridil hydrochloride has been shown to be a stomatocytic agent that causes endocytosis and lowers cell
|
Buy from Supplier |
Image Search Results
Journal: Cardiovascular Research
Article Title: Contractility measurements for cardiotoxicity screening with ventricular myocardial slices of pigs
doi: 10.1093/cvr/cvad141
Figure Lengend Snippet: Screening test with drugs from CiPA list with known interactions and risks performed in three different laboratories ( N = 3–5, n = 6–10). The effects of bepridil, cisapride, disopyramide, ibutilide, and risperidone (red) as well as negative controls DMSO and acetylsalicylic acid (black) were compared to time-matched controls treated only with PBS (grey). ( A ) Kaplan–Meier curve displaying the pacing capability of slices. Statistical analysis by Fisher’s exact test. ( B–H ) Mean and SEM of effects compared to PBS with a two-way ANOVA with Dunnett’s multiple comparison test on the normalized pacing threshold ( B ), normalized force ( C ), FFR ( D ), normalized contraction duration ( E ), CDFR ( F ), normalized ERP ( G ), and changes in diastolic force ( H ). Absolute values of each slice were normalized to values before adding the drug or solvent. Exact n and P values for each condition are given in , .
Article Snippet: Drugs from the CiPA list were added at five different concentration steps into 3–4 mL from the following stocks:
Techniques: Comparison, Solvent
Journal: Nature Communications
Article Title: MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calcium-associated autophagy
doi: 10.1038/s41467-018-06836-4
Figure Lengend Snippet: Cacna2d3 regulates survival of Mtb via Ca 2+ -mediated autophagy. a , b Bacterial survival of Mtb in ( a ) primary macrophages treated with Cacna2d3 siRNA; ( b ) macrophages from WT and Cacna2d3 mutant ( Cac3 PB/PB ) mice, after infection with Mtb (MOI = 5) for 24 h, compared to 2 h. c , d WT or Cac3 PB/PB macrophages were infected with Mtb , and then subjected to ( c ) TEM analysis; red arrow indicated the bacteria. ( d ) IB of lysates. e–h Confocal detection of mRFP-GFP-LC3B spots in Cacna2d3 -siRNA-treated macrophages ( e , f ) or Cac3 PB/PB macrophages, after infection with Mtb (MOI = 5) for 6 h ( g , h ); Bar, 5 μM. i Calcium assay in WT or Cac3 PB/PB macrophages infected with Mtb (MOI = 5) for the duration of 1 min. j , k CFU assay ( j ) and intracellular survival of Mtb ( k ) in WT or Cac3 PB/PB macrophages pretreated with Bepridil (BPD) (10 μM), and then infected with Mtb (MOI = 5) for 2 h or 24 h. l , m Confocal detection of mRFP-GFP-LC3B spots in WT or Cac3 PB/PB macrophages pretreated with DMSO or BPD infected with Mtb at MOI 5 for 6 h. Bar, 5 μM. n , o IB of lysates for phosphorylated-CaMKKβ ( n ) and phosphorylated-ULK1 ( o ) from WT or Cac3 PB/PB macrophages infected with Mtb for indicated times. NS, not significant ( p > 0.05), * p < 0.05 and ** p < 0.01 by the unpaired t -test ( f , h ) or Mann-Whitney U test ( a , b , j ). Data are from three independent experiments with biological duplicates in each ( a , b , f , h , j , k , m ; mean ± s.e.m. of n = 3 duplicates) or representative of three independent experiments ( c–e , g , i , l , n , o )
Article Snippet: The
Techniques: Mutagenesis, Infection, Bacteria, Calcium Assay, Colony-forming Unit Assay, MANN-WHITNEY